Obesity Drug Makers Vivus and Arena Just Can't Seem to Lighten Up

By Kapitall  OCT 10, 2013 12:20 PM

Vivus had a head start in promoting its obesity drug, but odds look better for Arena to reverse its decline. The question for investors with a longer time horizon is... when?


Author Chris Lau has position in ARNA.